Dr. Thorvardur R. Halfdanarson, MD

Dr. Halfdanarson practices at Mayo Clinic Hospital, Saint Marys Campus in Rochester, Minnesota, part of Mayo Clinic.

Dr. Halfdanarson's NPI, 1083684187, was assigned on January 23, 2006. Dr. Halfdanarson graduated from University of Iceland in 1995. Dr. Halfdanarson holds Minnesota license 45995.

Dr. Halfdanarson's primary practice is Mayo Clinic Hospital, Saint Marys Campus, at 1216 Second Street Southwest, Rochester, MN 55902 in Olmsted County. The practice phone is (507) 255-5123.

Dr. Halfdanarson's primary practice is Mayo Clinic Hospital, Saint Marys Campus in Rochester, Minnesota, part of Mayo Clinic. Dr. Halfdanarson is also affiliated with Mayo Clinic Health System in New Prague. The medical group on file is Mayo Clinic. Dmand AI also links Dr. Halfdanarson to 1 more hospice, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Halfdanarson practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Halfdanarson's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Halfdanarson is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Halfdanarson's licenses on file in 3 states: Minnesota, Arizona and Iowa.

Dmand AI lists breast cancer, chronic anemia, colorectal cancer, lung cancer, lymphoma, multiple myeloma and prostate cancer among the conditions Dr. Halfdanarson treats.

CMS data shows 31,222 Medicare services from Dr. Halfdanarson across 35 procedure codes in 2024, for 440 Medicare patients. Medicare paid $643,869 for them. Every service was in an office.

CMS counts 440 Medicare patients who saw Dr. Halfdanarson in 2024. The largest group is 65 to 74, with 241 patients. 67% of them have high blood pressure, and 59% have high cholesterol. 5% are also on Medicaid. Their average risk score is 2.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Halfdanarson's median patient age at 68, with 47% women.

In 2024, Dr. Halfdanarson wrote 153 Medicare Part D claims for 55 patients. 65% of them were for generic drugs. CMS names the drug for 69 of them, across 4 drugs with 11 or more claims each, at $165,361 in total drug cost. In 2023, CMS named 43 claims across 3 drugs.

Dr. Halfdanarson accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Halfdanarson as offering telehealth.

Dmand AI links 205 papers to Dr. Halfdanarson, published from 2005 to 2025. 2023 was the busiest year, with 26. The most frequent topics are Neuroendocrine Tumors, Pancreatic Neoplasms and Liver Neoplasms. Dr. Halfdanarson has published most often in Pancreas. Dr. Halfdanarson's most frequent co-authors are Mohamad Bassam Sonbol, MD, Mark J. Truty, MD and Rory L. Smoot, MD.

Dmand AI links Dr. Halfdanarson to 3 clinical trials. Conditions studied include Colonic Neoplasms, Gastrinoma and Glucagonoma.

CMS Open Payments shows 85 general payments to Dr. Halfdanarson from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 52% of the total. Exelixis Inc. paid the most, $18,084. It also lists 5 research payments totaling $11,487 from 2022 to 2025.

Dmand AI lists 1 award for Dr. Halfdanarson, most recently CMS Stage 1 EHR in 2011.

Dr. Halfdanarson graduated from University of Iceland in 1995. Dr. Halfdanarson is a member of AACR, ASCO, ASH, European Neuroendocrine Tumor Society (ENETS) and North American Neuroendocrine Tumor Society (NANETS).

Dr. Halfdanarson is in network with 17 carriers, including Elevance, Aetna and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.